Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | unknown | Phase 1 | 63 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Jun 27, 2024 | clinicaltrials |
| NCT05816499 | Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)(AK104IIT018) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06463171 | Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer | unknown | Phase 2 | 60 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT04818333 | A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 157 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 13, 2024 | clinicaltrials |
| NCT06313541 | Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy | unknown | Phase 2 | 146 | Fudan UniversityOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT04322578 | Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC(CONFIRM) | unknown | Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05818449 | Improvement of Personalized Lung Cancer Care Through Digital Connection and Patient Participation (DigiNet)(DigiNet) | unknown | N/A | 850 | University of CologneOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06441357 | Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT Parameter | unknown | — | 2,000 | Tang-Du HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06436885 | An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer | unknown | Early Phase 1 | 39 | Henan Cancer HospitalOTHER_GOV | 1 | May 31, 2024 | clinicaltrials |
| NCT06436040 | Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma | unknown | — | 40 | Tang-Du HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05878028 | L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC | unknown | Phase 2 | 33 | Quanli GaoOTHER_GOV | 1 | May 23, 2024 | clinicaltrials |
| NCT03724500 | Clinical Significance of Circulating Tumor Cell in Non Small Cell Lung Cancer | unknown | — | 65 | Chang Gung Memorial HospitalOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06424821 | Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC(LungCadX) | unknown | Phase 2 | 54 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT06422546 | A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC(pre-FLAME) | unknown | — | 950 | Beijing Cancer Prevention & Treatment SocietyOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04909073 | Observational Study of Afatinib 30 mg Daily | unknown | — | 69 | National University Hospital, SingaporeOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT06410040 | A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis | unknown | — | 28 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06406608 | Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer | unknown | N/A | 20 | Henan Cancer HospitalOTHER_GOV | 1 | May 9, 2024 | clinicaltrials |
| NCT06406660 | Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer | unknown | N/A | 20 | Henan Cancer HospitalOTHER_GOV | 1 | May 9, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT05443646 | Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients | unknown | Phase 2 | 55 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT06115239 | QOL After SURGERY and ADJUVANT Treatment | unknown | — | 200 | University of SalamancaOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT03833440 | Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance(PIONeeR) | unknown | Phase 2 | 114 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT04193956 | POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors(POINTING) | unknown | — | 3,500 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06394427 | Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer | unknown | — | 250 | West China HospitalOTHER | 0 | May 1, 2024 | clinicaltrials |
| NCT04622007 | Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)(KICKSTART) | unknown | Phase 2 | 68 | Effector TherapeuticsINDUSTRY | 3 | Apr 30, 2024 | clinicaltrials |
| NCT04085250 | Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy | unknown | Phase 2 | 264 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06374160 | Exercise in Patients With Advanced Non-small Cell Lung Cancer(BREATH) | unknown | N/A | 104 | University Hospital, EssenOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT05260606 | Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer(IBFIC) | unknown | — | 100 | Samsung Medical CenterOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06364046 | Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC | unknown | N/A | 56 | The Central Hospital of Lishui CityOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05240131 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 1 / Phase 2 | 88 | Galecto Biotech ABINDUSTRY | 3 | Apr 12, 2024 | clinicaltrials |
| NCT04909684 | Dose Tapering and Early Discontinuation to InCreAse cosT-effectIveness Of Immunotherapy for NSCLC(DEDICATION-1) | unknown | Phase 3 | 750 | Radboud University Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05519293 | Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05552781 | H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC | unknown | Phase 1 / Phase 2 | 76 | RedCloud BioINDUSTRY | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06357598 | Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer(PILOT) | unknown | Phase 4 | 30 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06349252 | Survival Validation and Gene Mutations of N Descriptors in the Ninth Edition of the TNM Classification for Lung Cancer | unknown | — | 1,263 | Fudan UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT02991924 | Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer | unknown | — | 600 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 4, 2024 | clinicaltrials |
| NCT05254119 | DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS(REGISTURK-LUNG) | unknown | — | 6,000 | Mahmut GumusNETWORK | 1 | Apr 4, 2024 | clinicaltrials |
| NCT04772235 | Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients(TOTEM) | unknown | Phase 1 | 32 | Instituto Oncológico Dr RosellOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06341387 | Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer | unknown | — | 200 | European Institute of OncologyOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341530 | Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 33 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341660 | To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06339242 | A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis | unknown | Phase 2 | 30 | Jiangsu Province Nanjing Brain HospitalOTHER | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06334757 | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | unknown | Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06323265 | A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer | unknown | — | 50 | Hebei Medical University Fourth HospitalOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06332287 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis | unknown | Phase 2 | 25 | Jiangsu Province Nanjing Brain HospitalOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06331650 | A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02619448 | Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC | unknown | Early Phase 1 | 12 | State University of New York - Upstate Medical UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06328049 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC | unknown | Phase 2 | 30 | Taixing People's HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Jun 27, 2024source: clinicaltrials